Biocryst Pharmaceuticals (BCRX) Total Current Liabilities (2010 - 2026)

Biocryst Pharmaceuticals has reported Total Current Liabilities for 17 years, with the latest figure at $195.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 39.71% year-over-year to $195.4 million; the trailing twelve-month figure through Mar 2026 stood at $195.4 million (up 39.71% YoY), and the FY2025 full-year result was $196.1 million, up 22.25% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $195.4 million, roughly flat from $196.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $196.1 million in Q4 2025, with the low at $81.0 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $132.0 million across 5 years, with a median of $129.1 million in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities sank 38.9% — and 2024, when it jumped 69.2%.
• Biocryst Pharmaceuticals' Total Current Liabilities stood at $105.5 million in 2022, then soared by 42.15% to $150.0 million in 2023, then increased by 6.93% to $160.4 million in 2024, then gained by 22.25% to $196.1 million in 2025, then retreated by 0.34% to $195.4 million in 2026.
• The last three Total Current Liabilities figures came in at $195.4 million (Q1 2026), $196.1 million (Q4 2025), and $190.2 million (Q3 2025), per Business Quant data.